The cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage lung tumours

Tamihiro Kamata*,†, Hong Jin‡, Susan Giblett, Bipin Patel, Falguni Patel, Charles Foster & Catrin Pritchard**

Abstract

The tumour microenvironment is known to play an integral role in facilitating cancer progression at advanced stages, but its function in some pre-cancerous lesions remains elusive. We have used the V600E BRAF-driven mouse lung model that develop premalignant lesions to understand stroma–tumour interactions during pre-cancerous development. In this model, we have found that immature macrophage-lineage cells (IMCs) producing PDGFA, TGFβ and CC chemokines are recruited to the stroma of premalignant lung adenomas through CC chemokine receptor 1 (CCR1)-dependent mechanisms. Stromal IMCs promote proliferation and transcriptional alterations suggestive of epithelial–mesenchymal transition in isolated premalignant lung tumour cells ex vivo, and are required for the maintenance of early-stage lung tumours in vivo. Furthermore, we have found that IMC recruitment to the microenvironment is restrained by the cholesterol-binding protein, Niemann-Pick type C2 (NPC2). Studies on isolated cells ex vivo confirm that NPC2 is secreted from tumour cells and is taken up by IMCs wherein it suppresses secretion of the CCR1 ligand CC chemokine 6 (CCL6), at least in part by facilitating its lysosomal degradation. Together, these findings show that NPC2 secreted by premalignant lung tumours suppresses IMC recruitment to the microenvironment in a paracrine manner, thus identifying a novel target for the development of chemopreventive strategies in lung cancer.

Keywords CCR1; lung adenoma; NPC2; tumour-associated macrophage-lineage cells; V600E BRAF

Subject Categories Cancer; Immunology; Respiratory System

Introduction

Oncogenic mutations are prevalent in human cancers, and some are thought to represent early mutations that initiate and subsequently drive cancer development. RAS and RAF oncogenes are amongst the best-characterised driver oncogenes and are mutated in a significant proportion of human cancers, notably pancreatic (~90%) and lung adenocarcinoma (~30%) in the case of KRAS (Malumbres & Barbacid, 2003), and melanomas (~50%) and thyroid cancers (~30%) in the case of BRAF (Davies et al., 2002). In contrast to KRAS, the incidence of BRAF mutations in human lung adenocarcinoma is relatively low (Naoki et al., 2002), but nearly a half of BRAF mutations in this type of cancer are the most common V600E BRAF mutation (COSMIC: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), suggesting that V600E BRAF contributes to lung carcinogenesis in some cases.

The mechanisms by which KRAS and BRAF oncogenes are involved in early-stage cancer development are beginning to be unravelled by analysis of genetically engineered mouse (GEM) models developing autochthonous tumours, especially for cancer types in which premalignant precursor lesions are difficult to access in humans. Lung adenocarcinoma is one such type of cancer in which atypical adenomatous hyperplasias (AAHs) are the purported precursor, but these early lesions are rarely diagnosed by non-invasive procedures (Gazdar & Brambilla, 2010). Instead, lung-specific expression of G12V KRAS or V600E BRAF in GEM models has provided evidence that activation of these oncogenes initially induces the formation of benign proliferative lesions after which the lesions enter a state of stable cell cycle arrest termed oncogene-induced senescence (OIS) (Collada et al., 2005; Dankort et al., 2007). While V600E BRAF-driven early lung lesions with OIS rarely progress to adenocarcinoma (Dankort et al., 2007), G12V KRAS-driven alveolar hyperplasias progress into malignant adenocarcinomas more frequently (Mainardi et al., 2014), which correlates well with the mutation spectrum of human lung adenocarcinomas. However, malignant progression of early lung lesions in the V600E BRAF model can be facilitated by mutations in key genes including depletion of...
tumour suppressor TRP53 (Dankort et al., 2007) or constitutive activation of β-catenin (Juan et al., 2014), indicating that these early lesions are indeed precursors for adenocarcinomas.

Although the difference between the G12V-KRAS and V600E-BRAF models with regard to malignant progression could be explained by the nature of intracellular signalling cascades activated by each oncoprotein (Trejo et al., 2012, 2013), cell-extrinsic inflammatory responses have also been shown to contribute to malignant progression of G12V-KRAS-driven early lesions, at least in a pancreatic cancer model (Guerra et al., 2011). In contrast, it still remains unclear how inflammatory or other environmental factors could influence the behaviour of V600E/BRAF-driven early-stage tumours with OIS. Whereas the microenvironment of advanced cancers, composed of a panoply of different cell types including hematopoietic (immune) cells, vascular components and activated fibroblasts, creates a pro-tumorigenic environment (Whiteside, 2008), there is growing evidence that immune cells in the microenvironment of pre-cancerous lesions could play a tumour-suppressive rather than tumour-promoting role. For example, CD4+ T-cell-mediated adaptive immunity in concert with monocytes/macrophages has been shown to execute the clearance of oncogenic NRAS-induced pre-cancerous lesions in the liver (Kang et al., 2011). In this model, early hepatic lesions exhibited biochemical characteristics of OIS including secretion of inflammatory chemo-cytokines (Kuilmann & Peeper, 2009), which likely contributed to the recruitment of the immune cells to the microenvironment. Such a suppressive microenvironment against pre-cancerous OIS lesions could potentially contribute to the less frequent malignant progression of V600E/BRAF-driven senescent lung adenomas.

To investigate the role of the tumour microenvironment in V600E/BRAF-driven premalignant lesions, we have taken advantage of our V600E/BRAF-driven autochthonous GEM model in which premalignant papillary adenomas accumulate in the lung. We show here that immature macrophage-lineage cells (IMCs) are recruited to the stroma of senescent lung adenomas through CCR1-dependent mechanisms. Unexpectedly, stroma IMCs are found to play a pro-tumorigenic role in vivo since the suppression of IMC recruitment through CCR1 inhibition profoundly decreases tumour burden. Furthermore, in a screen for proteins secreted from V600E/BRAF-expressing premalignant tumour cells, we identified the cholesterol-binding protein Niemann-Pick type C2 (NPC2). Our studies with NPC2 show it is secreted at high levels even at the pre-senescent stage, and is incorporated by IMCs wherein it regulates intracellular cholesterol levels and inhibits secretion of the CCR1 ligand, CC chemokine 6 (CCL6). This results in the suppression of IMC accumulation at the pre-senescent stage. Overall, the data point to a novel role of NPC2 in regulation of the pro-tumourigenic microenvironment.

Results

V600E/BRAF induces the formation of senescent lung adenomas

Conditional (Cre-loxP-regulated) knockin mice for oncogenic V600E/BRAF and G12V/G12S-KRAS have been recently generated by our group and others, and induction of oncogene expression in the lung in both models has been shown to induce premalignant lesions that up-regulate the expression of senescence markers (Collado et al., 2005; Dankort et al., 2007). To obtain an easily manipulated model for biochemical investigations, we utilised Braf+/LSL–V600E/CreER™ (BVE) mice since these developed large numbers of pulmonary adenomas in 100% of mice by spontaneous recombination of the Braf allele in the lung without tamoxifen induction (Fig 1A). Histologically, these tumours were identical to those induced by nasal administration of AdCre (Fig 1A). As previously reported for AdCre-induced tumours (Dankort et al., 2007), pulmonary adenomas in BVE mice exhibited signs of OIS at later stages, including significant loss of Ki67 expression (Fig 1B). These tumours did not stain for senescence-associated β-galactosidase or express p16INK4a or p19ARF at detectable levels but were positive for p21CIP1 and γH2AX (Supplementary Fig S1), suggesting that DNA-damage responses could be the major cause for the cell cycle arrest. Although most tumour cells at 10 weeks or later were negative for Ki67, a small population (2%) of Ki67+ tumour cells remained detectable at this later time point (Fig 1B).

For the most part, wherever possible, we utilised the CreER™ strain to induce V600E/BRAF expression rather than AdCre because of the known inflammatory phenotypes associated with AdCre delivery to the lung, even in wild-type mice (Mainardi et al., 2014). AdCre was only utilised in situations when the analysis required longer-term survival of mice (see below).

Immature macrophage-lineage cells expressing WT/BRAF are present in the stroma

Interestingly, the development of adenomas in both the BVE and Braf+/LSL–V600E/AdCre models was accompanied by the recruitment of non-tumour cells to the stroma (Fig 1A and C). The majority of these cells displayed an oval-shaped morphology with round nuclei.
Figure 1.

NPC2 restricts macrophage recruitment

© 2015 The Authors

EMBO Molecular Medicine
and a relatively low nuclear/cytoplasm ratio reminiscent of myeloid-lineage hematopoietic cells (Fig 1C). Stroma-specific staining with a myeloid marker Mac2 also supported their myeloid origin (Fig 1C).

We developed a method to separate the stroma cells from the tumour cells (Supplementary Fig S2) and found that the purified stroma cells were identical in morphology to those in histological sections, but rarely displayed indented nuclei or long cytoplasmic processes that are characteristic of monocytes or dendritic cells (DCs), respectively (Figs 1C and 2A). Cell surface marker analysis confirmed the expression of a myeloid marker CD11b at low levels in these cells, but other hematopoietic lineage markers, including Gr1, were not detected (Fig 2B). The lack of hematopoietic surface marker expression on the isolated stroma cells was not due to enzyme treatment during the isolation procedure since collagenase/DNase treatment of wild-type lung did not perturb the detection of CD11b<sup>hi</sup>Gr1<sup>hi</sup> neutrophils, CD11b<sup>Gr1</sup><sup>–</sup>F4/80<sup>–</sup> monocytes, CD3<sup>+</sup> or B220<sup>+</sup> lymphocytes or TER119<sup>+</sup> red blood cells (Supplementary Fig S3). These findings exclude the possibility that the stroma cells could belong to myeloid cell types with the CD11b<sup>Gr1</sup> phenotype, including neutrophils, inflammatory monocytes (DCs), respectively (Figs 1C and 2A). Cell surface marker analysis confirmed the expression of a myeloid marker CD11b at low levels (overlaid with isotype control histograms shown in grey). Scale bar, 25 µm.

In contrast, the stroma cells strongly expressed CD11c, a common marker for lung macrophages and DCs in mice (Misharin et al., 2013), whereas the macrophage marker F4/80 was not expressed (Fig 2C). Although the CD11b<sup>Gr1</sup>F4/80<sup>–</sup> phenotype was somewhat consistent with CD11b<sup>+</sup> DCs, we think this unlikely as CD24, a marker known to be expressed in circulating DC precursors (O’Keeffe et al., 2003) and lung DCs (Misharin et al., 2013) in mice, was also undetectable (Fig 2C). Instead, these cells weakly expressed CD206, a marker for alternative (M2-type) macrophage activation (Gabrilovich et al., 2012), but not CD86, a marker for DC maturation and classical (M1-type) macrophage activation (Gabrilovich et al., 2012) (Fig 2C). Collectively, the stroma cells did not show typical DC phenotypes but shared some characteristics with M2-polarised macrophages.

To further characterise the stroma cells, we cultured the isolated cells for 2 weeks without adding cytokines. The cells were efficiently maintained in these culture conditions, presumably because of support from autocrine chemo-cytokines and growth factors (see below), and developed larger-sized adherent cells (Fig 2D). Morphologically, these cells did not show dendritic cytoplasmic processes, but displayed abundant cytoplasm with numerous vacuoles (Fig 2D), consistent with a macrophage rather than DC morphology. Flow cytometry analysis of the cultured stroma cells demonstrated they maintained the CD11c<sup>Gr1</sup> phenotype with up-regulation of CD11b and acquisition of F4/80 expression (Fig 2E), suggesting macrophage differentiation. Although low-level expression of CD206 was maintained in culture, they also acquired CD86 expression (Fig 2E), indicating that macrophage differentiation of the stroma cells in culture was not skewed towards M1 or M2 polarisation. Although we cannot formally exclude the possibility that the stroma myeloid cells are CD11b<sup>Gr1</sup>F4/80<sup>–</sup> macrophage/DC progenitors (MDPs) (Fogg et al., 2006), CD11b expression on the stroma myeloid cells (Fig 2B) makes this unlikely.

In all, we ascribed these stroma cells the name immature macrophage-lineage cells (IMCs). PCR genotyping of the purified IMCs confirmed that they contained the unrecombined LSL-V600E allele but not the recombined Lox-V600E allele (Fig 2F), indicating that they solely express WT BRAF and not V600E BRAF, and thus accumulate as a reactive response to the oncogene-expressing lung tumours.

**Stroma IMCs secrete growth and EMT-promoting factors**

To explore the biological functions of IMCs, we co-cultured CMT64 mouse lung adenocarcinoma cells (Franks et al., 1976) with purified IMCs. IMCs enhanced the growth of these cells in a dose-dependent manner, and promoted fibroblast-like morphological changes suggestive of epithelial–mesenchymal transition (EMT) (Fig 3A). Some of the IMCs migrated into CMT64 cell sheets to establish cell-to-cell contacts (Fig 3A, right), and therefore, we assessed whether direct cell contacts were required for the phenotype. CMT64 cells cultured with IMC-conditioned media (IMC-CM) recapitulated the phenotypes (Fig 3B), indicating that secreted factors rather than cell-to-cell contacts are involved in this response. The IMC-CM also induced down-regulation of E-cadherin expression in the CMT64 cells as demonstrated by immunofluorescence (Fig 3B), consistent with an EMT-like response.

Alveolar type-2 (AT2) cells, the major epithelial cell type in V600E BRAF-driven lung tumours (Dankort et al., 2007), were also freshly isolated from BVE mice at 10 weeks p.p. using the fractionation method (Supplementary Fig S2). Isolated AT2 cells were validated by the presence of lamellar bodies containing pulmonary

---

**Figure 2. Characterisation of stroma IMCs.**

A Giemsa staining of isolated stroma IMCs. These cells show round or oval-shaped nuclei that lack indentations, and have an abundant basophilic cytoplasm without showing prolonging cytoplasmic processes, suggestive of immature myeloid-lineage cells that are morphologically distinct from monocytes/DCs. Scale bar, 25 µm.

B Cell surface marker analysis of IMCs showing lack of common hematopoietic marker expression except for CD11b, which is expressed at low levels (overlaid with isotype control histograms shown in grey).

C Cell surface marker analysis (dot plots) of IMCs demonstrating CD11c<sup>+</sup> IMCs do not express macrophage (F4/80, DC (CD24) or M1-polarisation (CD86) markers, but weakly express the M2 marker CD206. Insets show isotype control staining.

D Morphological evaluation of IMCs cultured for 2 weeks without additional cytokines. The cells grown on culture plates were imaged by phase-contrast microscopy (left). Then, the cells were trypsinised and smeared on glass slides for Giemsa staining (right). These cells are intermediate to large sized, round or amoeboid cells with cytoplasmic vacuoles, consistent with a macrophage morphology. Scale bars, 50 µm.

E Cell surface marker analysis of cultured IMCs showing differentiation into F4/80<sup>+</sup> macrophages with CD11b<sup>Gr1</sup>F4/80<sup>C0</sup>CDC86<sup>C0</sup>CD206<sup>C0</sup> surface phenotype (overlaid with isotype control histograms shown in light grey).

F PCR detection of Braf recombination in purified IMCs, AT2 cells and tumour cell aggregates.

Source data are available online for this figure.
Figure 2.
surfactants visualised by Papanicolau staining and flow cytometry 
detection of surfactant protein C (SPC) (Supplementary Fig S2C 
and D). At this stage, AT2 cells were largely growth-arrested 
(Fig 1B), but the small proliferating pool (~2%) was detected by 
in vitro BrdU labelling (Fig 3C). When these cells were co-cultured 
with autologous IMCs using a Transwell culture system, there 
was an approximate doubling of BrdU⁺ proliferating cells, and 
the expression of EMT markers was also up-regulated (Fig 3C).
In addition to EMT/growth-promoting factors, CC chemokines (e.g. TGF-β, PDGFA, CTGF) (Supplementary Table S1). Secretion of TGF-β and PDGFA was further validated by immunoblotting (Supplementary Fig S5A and B). Secreted proteins previously linked with M2 macrophages and MDSCs (chitinase-3-like 3, arginase-1, S100A9) (Gordon, 2003; Ostrand-Rosenberg & Sinha, 2009) were also identified (Supplementary Table S1). These findings consolidate the M2-polarised nature of the IMCs as well as their potential to promote growth/EMT through paracrine mechanisms.

**CCR1 signalling is required for IMC recruitment and premalignant tumour development**

In addition to EMT/growth-promoting factors, CC chemokines CCL6, 7 and 9 were identified in the IMC-CM by mass spectrometry (Supplementary Table S1), and secretion of CCL6 was validated by immunoblotting (Supplementary Fig S5C). CCL6, 7 and 9 are known to be ligands for the chemokine receptor CCR1 (Bera-hovich et al., 2005). We therefore assessed CCR1 expression using immunofluorescence of separated IMCs/AT2 fractions and immunohistochemistry of BVE lung tissue (Fig 4A and B). Together, these data confirm predominant expression of CCR1 in IMCs, some of which is localised at the plasma membrane along with Mac2, and very little, if any, expression in V600EBRAF-expressing cells in inhibitor-treated mice displayed low side-scatter profiles (Fig 4E right), suggesting that IMCs with increased intracellular granularity were mostly depleted from the lung by the inhibitor. These data demonstrate an essential role for CCR1 signalling in the recruitment of IMCs and support a role for the IMCs in the in vivo maintenance of premalignant lung adenomas in this system.

To investigate the role of CCR1 signalling in IMC recruitment, we treated AdCre-infected BrafV600EBRAF mice with the CCR1 inhibitor J-113863 (Amat et al., 2006), initiated at 5 weeks following AdCre induction before overt IMC accumulation appeared in the lung. AdCre delivery was used to induce V600EBRAF expression in this particular experiment rather than intercrossing with the CreER<sup>tm</sup> strain since the compromised health conditions of the BVE mice, often as early as immediately after weaning, did not allow us to perform consecutive i.p. drug injections. CT imaging and histological analysis after 4 weeks of treatment showed not only the suppression of IMC recruitment but decreased tumour burden (Fig 4C and D), which was further validated by flow cytometry quantification of CD11c<sup>+</sup> IMC and SPC<sup>+</sup> AT2 cells (Fig 4E and F) and tumour area quantification of histological sections (Supplementary Fig S6). Of note, the majority of the remaining lung CD11c<sup>+</sup> cells in inhibitor-treated mice displayed low side-scatter profiles (Fig 4E right), suggesting that IMCs with increased intracellular granularity were mostly depleted from the lung by the inhibitor. These data demonstrate an essential role for CCR1 signalling in the recruitment of IMCs and support a role for the IMCs in the in vivo maintenance of premalignant lung adenomas in this system.

Single-dose AdCre administration into the mouse lung has been reported to cause inflammatory lymphocyte infiltrations that are persistent for at least 4 weeks in wild-type mice and for up to 24 weeks in KRAS<sup>G12V</sup> mice (Mainardi et al., 2014). Consistent...
Figure 4.

IMCs (CD11c+) and AT2 (SPC+) cell numbers (x10^6/lung):

- IMCs (CD11c+): Vehicle vs. CCR1 inhibitor, P=0.007
- AT2 (SPC+): Vehicle vs. CCR1 inhibitor, P=0.0007

Percentage of total lung cells:

- CD4: Vehicle vs. CCR1 inhibitor, P=0.91
- CD8: Vehicle vs. CCR1 inhibitor, P=0.54
with this, we detected increased T lymphocytes in the lungs of wild-type and Braf\textsuperscript{−/LSL-V600E} mice at 9–13 weeks after single-dose AdCre administration (Supplementary Fig S7). Since CCR1 blockade is known to inhibit recruitment of not only macrophages but also CD4\textsuperscript{+} T-cells to nephritic kidneys in an autoimmune disease mouse model (Bignon et al., 2014), we were concerned that the phenotype observed in our experiments could be attributed to effects on the T-cell populations rather than IMCs. We therefore analysed the % CD4\textsuperscript{+} and %CD8a cells but found that these were not significantly affected by CCR1 inhibition in the lungs of Braf\textsuperscript{+/LSL-V600E}/AdCre mice (Fig 4G). These data suggest that it is the IMCs rather than T-cell populations that are the primary target of the CCR1 inhibitor in our experiments.

**V600E BRAF-driven lung adenomas secrete the cholesterol-binding protein NPC2**

We then sought to identify secreted factors from the tumours that may be involved in an interaction with the IMCs. To this end, we generated CM of whole lung tissues (WL-CM) obtained from BVE mice at 6 weeks p.p. (Supplementary Fig S8) when increased tumour burden with relatively modest IMC accumulation is observed (Fig 1A). WL-CM was also generated from wild-type mice as a control. 13 proteins uniquely secreted into the BVE WL-CM were identified by mass spectrometry (Supplementary Table S2). We therefore focused on the cholesterol-binding protein NPC2 since this protein was detected at high levels in the BVE WL-CM by immunoblotting (Fig 5A top). Robust induction of NPC2 protein expression in total BVE lung tissue was readily detectable as early as 3 weeks p.p. (Fig 5A) before clear OIS responses were observed in the tumours (Fig 1B).

To confirm the cell population secreting NPC2, we generated CM from AT2-enriched culture (AT2-CM) (Supplementary Fig S2) and compared NPC2 protein levels in AT2-CM to that in IMC-CM. As shown in Fig 5B, NPC2 protein was detected only in AT2-CM by immunoblotting. In line with this, NPC2 mRNA was expressed at ~7-fold higher levels in AT2 cells compared to IMCs as assessed using qRT–PCR (Fig 5C). However, unexpectedly, intracellular NPC2 protein levels were higher in freshly isolated IMCs than AT2 cells (Fig 5D). Interestingly, intracellular NPC2 protein levels in IMCs were dramatically decreased during 48 h of culture (Fig 5E), indicating that the relatively low Npc2 mRNA transcript levels in IMCs (Fig 5C) were not sufficient for maintaining intracellular protein levels in freshly isolated IMCs. In contrast, when IMCs were cultured with purified bovine NPC2 (bNPC2), NPC2 protein accumulated in the cells (Fig 5F), suggesting active uptake of extracellular NPC2 protein by IMCs. IMC uptake of extracellular NPC2 was further confirmed by culturing freshly isolated IMCs with fluorochrome-conjugated, recombinant NPC2 (Huang et al., 2014) (Fig 5G), whereas endogenous Npc2 transcription in IMCs was not significantly affected by bNPC2 treatment (Fig 5H). These ex vivo findings suggest that NPC2 secreted by the AT2 cells can be incorporated by the IMCs, resulting in the increase of intracellular NPC2 protein in freshly isolated IMCs (hypothetical model is shown in Fig 5I).

**NPC2 restrains IMC accumulation**

To investigate the biological role of NPC2 in V600E BRAF-driven lung tumourigenesis, we crossed BVE mice with Npc2 hypomorphic mice (Sleat et al., 2004). BVE mice on the Npc2\textsuperscript{hypo/hypo} background showed a significantly shortened life span compared to Npc2\textsuperscript{+/+} BVE mice (log-rank P = 0.0387), while Npc2\textsuperscript{+/hypo} BVE mice tended to have shortened survival compared to the Npc2\textsuperscript{+/+} counterparts (Fig 6A), though this was not at a statistically significant level (log-rank P = 0.143). We excluded the Npc2\textsuperscript{hypo/hypo} BVE cohort from further analysis because of the inability to obtain significant numbers of mice due to reduced survival, particularly at later time points when stromal IMC accumulation is evident. We were also concerned that the range of non-respiratory symptoms known to be evident in Npc2\textsuperscript{hypo/hypo} animals (Sleat et al., 2004; Griese et al., 2010) would complicate phenotype analysis. Our further studies therefore focused on the BVE Npc2\textsuperscript{+/hypo} cohort.

Histological analysis at 5 weeks p.p. revealed accelerated accumulation of stroma IMCs in the lung of mice on the Npc2\textsuperscript{+/hypo} background (Fig 6B). Flow cytometry analysis of CD11c\textsuperscript{+} cells confirmed there was a significant increase in the number of stroma IMCs in the lungs of Npc2\textsuperscript{+/+} BVE mice compared to Npc2\textsuperscript{+/+} mice throughout their life span (Fig 6C). Quantitation of the immunofluorescence co-staining of Mac2 with nuclear Ki67 demonstrated a modest but statistically significant decrease of %Ki67+ in

---

**Figure 4. CCR1 inhibition suppresses IMC recruitment and tumour development in vivo.**

A CCR1 immunofluorescence of primary IMCs (left, co-stained with Mac2) and AT2 cells (right, co-stained with E-cadherin) detected by CLSM. Scale bars, 10 μm. CCR1 staining was mainly detected in cytoplasmic vesicles within IMCs, but some CCR1 fluorescence was also detected at the plasma membrane along with Mac2 (inset in the left microphotograph).

B CCR1 immunohistochemistry of lung sections from BVE mice showing CCR1 expression in stroma IMCs. Scale bar, 50 μm.

C CLSM imaging of lungs of AdCre-infected Braf\textsuperscript{+/LSL-V600E} mice treated with vehicle (top) or CCR1 inhibitor (bottom). H: heart, * indicates a tumour region accompanied byatelectasis.

D H&E staining of lung sections from vehicle (left) or CCR1 inhibitor (right) treated AdCre-infected Braf\textsuperscript{+/LSL-V600E} mice. Scale bars, 250 μm (top) or 50 μm (bottom).

E Flow cytometry analysis of CD11c\textsuperscript{+} (top, green) and SPC\textsuperscript{+} (bottom, red) cells in the lung of AdCre-infected Braf\textsuperscript{+/LSL-V600E} mice treated with vehicle (left) or CCR1 inhibitor (right).

F Lung CD11c\textsuperscript{+} (left) and SPC\textsuperscript{+} (right) cell numbers (per left lobe) were quantitated in AdCre-infected Braf\textsuperscript{+/LSL-V600E} mice treated with CCR1 inhibitor or vehicle (n) (n = 3, mean + SD).

G % Lung CD4\textsuperscript{+} (left) and CD8\textsuperscript{+} (right) T lymphocytes were quantitated in AdCre-infected Braf\textsuperscript{+/LSL-V600E} mice treated with CCR1 inhibitor or vehicle (n) (n = 3, mean + SD).

Source data are available online for this figure.
Figure 5.

NPC2 restrains macrophage recruitment

Tamihiro Kamata et al

Published online: July 16, 2015
Mac2⁺ cells (Fig 6D), suggesting that enhanced recruitment, rather than local proliferation, is the basis for the stroma phenotype. Consistently, the CD11c⁺ population in the Npc2⁺/hypo BVE lung also had reduced BrdU incorporation in vivo (Fig 6E).

Neither AT2 cell number nor their ability to incorporate BrdU was altered in Npc2⁺/hypo BVE mice at the pre-senescent stage of tumour development (5 weeks p.p.; Supplementary Fig S9), demonstrating that NPC2 does not regulate the intrinsic growth of the pre-malignant tumour cells, at least at the pre-senescent stage. Furthermore, the data show that pre-senescent AT2 cells are largely insensitive to the growth-promoting effects of IMCs in vivo. At this pre-senescent stage of 5 weeks p.p., most tumours are still actively proliferating (Fig 1B), but a few of them show the earliest signs of OIS, represented by a loss of nuclear Ki67 staining. Interestingly, at this time point, Mac2⁺ IMCs on the Npc2⁺/hypo background were often found co-located with a limited number of Ki67 tumour cells within tumour interstices that had largely lost Ki67 positivity (Fig 6F). This possibly indicates that the IMCs have a direct effect on AT2 cells pre-disposed to proliferation at the senescent stage.

Less than 20% of BVE mice on the Npc2⁺/hypo background survived until the senescent stage (9–10 weeks p.p.) (Fig 6A), Therefore, to accurately evaluate the effect of reduced NPC2 expression at later stages when senescent levels are higher, we utilised Braf⁺/Lsladin/-AdCre mice on the Npc2⁺/hypo background, most of which survived for more than 10 weeks after AdCre delivery. In this setting, decreased NPC2 expression significantly enhanced IMC accumulation and also gave rise to increased AT2 cell number in five out of seven mice compared to the average of Npc2⁺/⁺ counterparts, though this difference was not statistically significant due to the variability of the tumour burden of Npc2⁺/hypo animals (Fig 6G).

We also measured tumour burden of Npc2⁺/⁺ and Npc2⁺/hypo BVE lung by tumour area quantification using histological sections, leading to the same conclusion (Supplementary Fig S6C).

**Exogenous NPC2 decreases cholesterol levels in IMCs**

NPC2 is known to regulate cholesterol trafficking from the late endosomes/lysosomes (LE/Ly) to the cytosol (Subramanian & Balch, 2008), and a homozygous null mutation in NPC2 causes cholesterol accumulation in LE/Ly in fibroblasts (Naureckiene et al., 2000). Therefore, we assessed whether uptake of exogenous NPC2 by IMCs alters un-esterified cholesterol levels. To this end, we utilised Npc2⁺/hypo IMCs since accumulation of un-esterified cholesterol is readily detectable by vesicular filipin staining of variable size (Fig 7A). In untreated Npc2⁺/hypo IMCs, coarse filipin staining was surrounded by LAMP2 reticular structures (Fig 7B), but was not associated with LAMP1 or other organelle markers (Supplementary Fig S10), indicating that un-esterified cholesterol accumulation is localised at LAMP2 LAMP1 structures that are distinct from LAMP1 lysosomes. Interestingly, the filipin-stained structures partially associated with vertical F-actin-based columns (Supplementary Fig S11) suggestive of podosomes that form constitutively in M2 macrophages (Linder & Wiesner, 2015) and have been functionally linked with lysosomes (Cougoule et al., 2009; Tu et al., 2008). Following treatment with purified bNPC2, filipin staining in cytoplasmic vesicles was significantly reduced (Fig 7C), demonstrating that exogenous NPC2 can decrease free cholesterol accumulated even at non-lysosomal structures in IMCs.

**Exogenous NPC2 inhibits CCL6 secretion in IMCs**

Given the previously established function of NPC2 in intracellular cholesterol trafficking, a role in regulation of IMC recruitment is somewhat unusual. However, a link between cholesterol and chemokine secretion in macrophages has been previously documented in atherosclerotic lesions (Moore & Tabas, 2011). As IMC accumulation is dependent on CCR1 signalling (Fig 4), we investigated the effect of NPC2 on the secretion of CCR1 ligand CCL6. CCL6 secretion was significantly attenuated when exogenous bNPC2 was added to IMC cultures (Fig 8A). Consistent with this, CCL6 secretion levels increased significantly during 24–72 h of IMC culture without exogenous NPC2 (Fig 8B) when intracellular NPC2 levels are known to be robustly decreased (Fig 5E). Thus, CCL6 secretion inversely correlates with intracellular NPC2 protein levels. Ccl6 mRNA levels were not affected by NPC2 treatment (Fig 8C), suggesting intracellular CCL6 processing at the post-translational level is involved.

To examine the mechanistic basis for this phenotype, we investigated CCL6 subcellular localisation in cultured IMCs. When IMCs...
Figure 6.
were cultured without bNPC2, CCL6 showed vesicular distribution, mostly devoid of LAMP1 staining. Following bNPC2 treatment, CCL6/LAMP1 co-localisation was detected at perinuclear regions and cytoplasmic vesicles (Fig 8D). The perinuclear CCL6 staining was confirmed to be not only within Golgi-related structures stained with a Golgi-cisternae marker giantin or a trans-Golgi network marker TGN46, but also at non-Golgi (giantin/TGN46-) vesicular structures (Supplementary Fig S12) that may include perinuclear lysosomes. These findings suggest that CCL6 could be targeted to the lysosomes by exogenous NPC2. To validate the functional contribution of the lysosome to decreased CCL6 protein levels, we treated IMCs with baflomycin A1 (Baf-A1) to interfere with lysosomal functions by inhibiting vesicular acidification. As shown in Fig 8E, Baf-A1 treatment rescued intracellular CCL6 protein levels in IMCs treated with exogenous NPC2, indicating that the NPC2-induced reduction in intracellular CCL6 protein is attributable, at least in part, to lysosomal degradation. CCL6/LAMP1 dual staining of bNPC2-loaded, Baf-A1-treated IMCs also showed co-localisation of CCL6 and LAMP1 more clearly (Supplementary Fig S13) than those without Baf-A1 treatment (Fig 8D), further supporting the role of lysosomal degradation in CCL6 reduction. Interestingly, vesicular CCL6 staining in the periphery of the cytoplasm did not co-localise with LAMP1 in bNPC2-loaded, Baf-A1-treated IMCs (Supplementary Fig S13), implying that vesicular acidification may be required for CCL6 to be fully transferred to the lysosomes. In contrast to the intracellular protein levels, CCL6 secretion into the CM was not rescued by Baf-A1 (Fig 8E), further supporting the role of lysosomal degradation (in vivo) and CCL6 secretion by these cells. This has important consequences since accumulation of IMCs relies on signals through the CCL6 receptor, CCR1 (Fig 4). Thus, NPC2 secreted by pre-malignant lung tumours interferes with the tumour microenvironment through paracrine mechanisms.

Tumour-associated macrophages (TAMs) are the major myeloid cell type in the tumour microenvironment (Grivennikov et al., 2010), and most TAMs are considered to be M2-like macrophages (Biswas & Mantovani, 2010). The IMCs described here are morphologically distinct from TAMs, but their CD11b+CD11c+ surface phenotype is similar to TAMs in a mammary tumour model recently reported (Franklin et al., 2014). IMCs in our model also secrete M2 marker proteins including YM1, arginase-1, MRC1 (soluble CD206) and legumain (Luo, 2006; Biswas & Mantovani, 2010; Murray & Wynn, 2011) (Supplementary Table S1) and promote tumour cell growth in vitro and ex vivo (Fig 3). Furthermore, the in vivo targeting of IMCs by the CCR1 inhibitor effectively suppressed tumour progression in vivo (Fig 4) in a similar way to the targeting of TAMs in the oncogenic KRAS-induced lung adenocarcinoma model (Cortez-Retamozo et al., 2012). This demonstrates for the first time that lung cancer progression relies on tumour-associated macrophage-lineage cells not only at advanced stages but also at pre-malignant stages. Interestingly, TAMs in the KRAS model were derived from the spleen through CCR2 signalling (Cortez-Retamozo et al., 2012), whereas the recruitment of IMCs in our model is dependent on CCR1 signalling (Fig 4). Since CCR1 is essential for myeloid progenitor mobilisation (Gao et al., 1997), it is plausible that myeloid progenitors are redistributed to the lung by CCR1 signalling and thereby serve as precursors for IMCs.

Using ex vivo studies, we have shown that IMCs have pro-tumourigenic properties by promoting the growth and EMT of AT2 cells in culture (Fig 3) and abrogation of IMCs by the CCR1 inhibitor provides clear evidence for the pro-tumourigenic/tumour-supportive functions of IMCs (Fig 4). However, the Npc2+/hypo BVE mice

Discussion

NPC2 is a small glycoprotein that was initially identified as a secretory protein in epididymal fluid and later characterised as the product of the second defective gene in Niemann-Pick type C (NPC) disease. Because of the early death of NPC patients suffering from severe neurodegeneration (Vanier, 2010), predisposition to cancer has been difficult to assess although several sporadic cases have been reported to develop malignancies (Birch et al., 2003). Intracellular NPC2 protein is known to regulate cholesterol transport from the LE/Ly to the cytosol, and the incorporated extracellular NPC2 protein is known to impart functional properties to NPC2-deficient fibroblasts in the same manner as the endogenously expressed protein (Naureckiene et al., 2000). Although such in vitro studies suggest that secreted NPC2 exerts its biological functions through autocrine/paracrine mechanisms, in vivo evidence for this is lacking. In this study, we have found that V600EBRAF-driven early-stage lung tumours abundantly secrete NPC2 protein and that the secreted NPC2 protein is incorporated by stromal IMCs, suppressing CCL6 secretion by these cells. This has important consequences since accumulation of IMCs relies on signals through the CCL6 receptor, CCR1 (Fig 4). Thus, NPC2 secreted by pre-malignant lung tumours interferes with the tumour microenvironment through paracrine mechanisms.

![Figure 6](image_url) Npc2 haploinsufficiency causes stroma IMC accumulation.

A Shortened survival of BVE mice following reduction in Npc2 gene dosage. Genotypes of mice are as follows: +/+ = Braf^+/+;CreER^+/+;Npc2^+/+, +/hypo = Braf^+/+;CreER^+/+;Npc2^+/hypo, hypo/hypo = Braf^+/hypo;CreER^+/+;Npc2^+/hypo. Median survival time (MST) for each genotype is indicated.

B Representative H&E staining of lung sections from 5-week-old BVE mice on the Npc2^+/+ (+/+ or Npc2^+/hypo (+/+hypo) background) is shown. Scale bars, 500 μm.

C Stroma IMC quantification per lung in Npc2^+/+ (+/+ or Npc2^+/hypo (+/+hypo) BVE mice at different ages (39–109 days p.p.).

D Ki67/Mac2 immunofluorescence analysis of Npc2^+/+ (+/+ or Npc2^+/hypo (+/+hypo) BVE lung sections at 5 weeks of age. Simultaneous images for Ki67 (green), Mac2 (red) and DAPI (blue) are indicated. Arrows indicate dual positive cells for nuclear Ki67 and Mac2. Scale bars, 50 μm. The bar chart indicates the % Ki67/Mac2 stroma cells (mean ± SD), obtained from 4 independent Npc2+/+ and Npc2+/hypo BVE pairs.

E In vivo BrdU incorporation of CD11c+ IMCs from Npc2^+/+ (+/+ or Npc2^+/hypo (+/+hypo) BVE mice are shown. Representative flow cytometry plots of three independent experiments are indicated.

F Ki67 (green)/Mac2 (red) dual immunofluorescence staining of lung sections from 5-week-old Npc2+/hypo BVE mice with nuclear DAPI (blue) staining, focusing on intratumour Mac2+ cells. Scale bar, 50 μm. Enlarged images of the boxed areas 1 and 2 highlight Ki67+ Mac2+ cells associated with Mac2+ cells (arrows).

G Lung SPC/CDC11c cell numbers of Npc2+/+;CreER^+/+;Npc2^+/+ (+/+ or n = 3) and Npc2+/hypo;CreER^+/+;Npc2^+/hypo (+/+hypo, n = 7) mice at 10 weeks post-AdCre infection.

Source data are available online for this figure.
NPC2 reduces intracellular cholesterol accumulation in IMCs.

A Intracellular un-esterified cholesterol distribution as detected by filipin staining in freshly isolated Npc2+/+ and Npc2+/hypo IMCs. Scale bars, 25 μm. Filipin-stained cells were graded from 0 to 3+ as indicated in the microphotographs (see Materials and Methods for criteria), and % of each grade in IMCs from Npc2+/+ (+/+) and Npc2+/hypo (+/hypo) BVE mice is shown in the bar chart. The data were obtained by analysing 176 Npc2+/+ and 242 Npc2+/hypo IMCs from three independent Npc2+/+ and Npc2+/hypo pairs.

B CLSM imaging of fresh Npc2+/hypo IMCs stained with filipin (cyan) and LAMP2 immunofluorescence (purple). Scale bars, 5 μm. Coarse structures strongly stained with filipin are surrounded by cytoplasmic membranous staining of LAMP2. Single-colour greyscale images are also demonstrated in the middle (filipin) and right (LAMP2).

C Intracellular un-esterified cholesterol distribution as detected by filipin staining in Npc2+/hypo IMCs cultured with or without 50 μg/ml bNPC2 for 48 h. Scale bars, 25 μm. Quantitative data in the bar graph were obtained by analysing 265 bNPC2-untreated (-bNPC2) and 252 bNPC2-treated (+bNPC2) cells from three independent cultures using the method described in (A).

Source data are available online for this figure.
Figure 8.

NPC2 restrains macrophage recruitment.
Figure 8. NPC2 inhibits IMC secretion of CCL6.

A Immunoblot (left) and ELISA (right; n = 3) analyses of CCL6 in IMC-CM from primary Npc2+/+ IMCs cultured with or without 50 μg/ml bNPC2 for 48 h (immunoblots) or 72 h (ELISA). The data in the bar graph (ELISA) represent mean + SD.
B Quantification of secreted CCL6 into IMC-CM during the initial 24 h (0–24 h) and subsequent 48 h (24–72 h) of IMC culture by ELISA (n = 3, mean + SD).
C Immunoblot and qRT-PCR analyses of CCL6 expression in Npc2+/+ IMCs cultured with or without 50 μg/ml bNPC2 for 48 h. The data in the bar graph (qRT-PCR) represent mean + SD; n = 3.
D CLSM imaging of CCL6 (green)/LAMP1 (red) immunofluorescence of Npc2+/+ IMCs cultured with or without 50 μg/ml bNPC2 for 48 h. Scale bars, 10 μm. The right bottom image highlights the boxed area of the merged image of bNPC2-treated IMCs showing partial co-localisation of LAMP1 and CCL6.
E Immunoblot analysis of intracellular and secreted (CM) CCL6 in baflomycin-treated Npc2+/+ IMC culture. IMCs without (left) or with (right) 50 μg/ml bNIPC2 pre-loading for 30 min were chased in serum-free DMEM for 3 h and then treated with 200 nM baflomycin A2 for 2 h.

Source data are available online for this figure.

demonstrate IMC amplification by ~2- to 6-fold without significant enhancement of tumour progression or AT2 growth (Fig 6). We believe this latter observation does not challenge the pro-tumorigenic/tumour-supportive role of IMCs but, rather, suggests this level of amplification of IMCs is not sufficient to give a dramatic in vivo response and/or the tumour response and IMC quantity do not show a linear correlation in vivo. Altogether, our data show a clear role for the IMCs in tumour maintenance, but a function of these cells in further tumour progression and escape from OIS is currently not clear from our analysis.

The tumour cells were identified to secrete a number of factors, although senescence-associated secretory proteins (SASPs) previously identified (Kuilman & Peeper, 2009) were not detected within our data set (Supplementary Table S2). The most likely explanation for this is that we analysed lung tissue containing tumours that were not fully senesced at 6 weeks of age. We focused on NPC2 since this cholesterol-binding protein has not previously been characterised in the context of lung tumourigenicity. Although NPC2 is secreted at high levels by V600E-RAF-expressing AT2 cells, IMC accumulation is still evident, which would suggest that the protein is not the only chemo-attractant factor regulating IMC recruitment.

We speculate that IMC recruitment could be initiated by factors derived from non-IMC cells before being robustly facilitated by autocrine CCL6. Secretion of such factors may be regulated independently of NPC2.

NPC2 has been previously reported to be abundantly secreted by human and mouse lung adenocarcinoma cells (Taguchi et al, 2011). Although this previous study detected NPC2 secretion from human lung adenocarcinoma cell lines (Taguchi et al, 2011), it remains unclear if NPC2 secretion levels could be altered by the oncogenic mutation status and/or disease progression. Since our data suggest that NPC2 could potentially be a tumour suppressor that functions at pre-malignant stages, quantitative evaluation of NPC2 secretion by lung tumours at different developmental stages will be important. To this end, oncogenic KRAS-driven lung tumour models will be useful since the progression of early precursor lesions into malignant adenocarcinoma can be tracked in these models (Jackson et al, 2001; Mainardi et al, 2014). A comparison between KRAS and BRAF models may also provide insight into whether different driver oncogenes alter NPC2 expression/secretion and potentially affect the microenvironment and malignant progression of early lung lesions. These experiments are currently underway in our laboratory.

Based on our present study, we hypothesise that human lung AAH lesions, the precursors for adenocarcinomas, may respond to chemopreventive interventions targeting the microenvironment with CCR1 inhibitors, NPC2 protein itself or chemicals that up-regulate NPC2 expression. CCR1 inhibitors have already entered clinical trials for the treatment of autoimmune diseases such as rheumatoid arthritis (Tak et al, 2013) and so have the potential to be tested in a lung cancer setting. A number of new therapeutic strategies against NPC disease are being experimentally investigated, including histone deacetylase inhibitors that increase NPC protein expression (Pipalia et al, 2011). Such chemical compounds may also effectively target tumour-associated macrophage-lineage cells in early-stage precursors for lung adenocarcinomas, through increasing NPC protein expression. Further investigations and translational studies will be needed to explore the clinical relevance of our animal study and the chemopreventive potentials of chemical compounds targeting CCR1 and the NPC pathway.

Materials and Methods

Animals

All animal experiments were performed under UK Home Office License authority. BrafV600E/CreERT2 (Mercer et al, 2005), CCAG-CreER2tm (Hayashi & McMahon, 2002) and Npc2 hypomorph (Seal et al, 2004) mice were genotyped as reported. Male and female mice were randomly selected for each experiment. Unless otherwise stated, all experiments on BVE mice utilised animals of 9–10 weeks of age. Nasal delivery of AdCre was performed as described (Dankort et al, 2007) on mice at 8–10 weeks of age. 8 mg/kg of CCR1 inhibitor J-113863 (Tocris Bioscience) dissolved in phosphate-buffered saline (PBS) with 5% DMSO (Sigma) and 5% Cremophor®EL (Sigma) was injected intraperitoneally 5 days/week for 4 weeks starting at 5 weeks after AdCre administration. Lung tissues were processed for H&E staining and immunohistochemistry (IHC) as described (Mercer et al, 2005), except for CCR1 IHC for which the Novolink™ Polymer Detection System (Leica Biosystems) was used according to manufacturer’s instructions. Antibodies used for IHC are described in Supplementary Methods. μCT imaging of mice was performed using a Quantum FX μCT system (PerkinElmer).

Cell culture

All cultures were performed in DMEM with 10% FCS, unless otherwise described. CMT64 cells were obtained from Cell Service
at Cancer Research UK. Bovine NPC2 (bNPC2) was added to cultures at 50 μg/ml. Co-cultures of CMT64/IMCs were performed in 12-well plates with 1 × 10⁴ CMT64 cells and 1.5–3 × 10⁵ IMCs. For co-culture of primary AT2 cells with IMC/lung fibroblasts using 6-well Transwell™ plates (0.4 μm pore, Corning), 2 × 10⁶ IMCs or 6 × 10⁵ lung fibroblasts were plated into bottom wells, and 3 × 10⁵ AT2 cells were added in transwell inserts. For NPC2 uptake experiments, NPC2-Alexa488 was added to IMCs at 82.5 nM. For bafilomycin A1 (Baf-A1, Sigma), IMCs pre-loaded with bNPC2 (50 μg/ml) for 30 min were chased in serum-free DMEM for 3 h and then incubated with 200 nM Baf-A1 for 24 h.

**Flow cytometry**

Cell surface markers were analysed by flow cytometry as described (Kamata et al., 2010). Antibodies used for flow cytometry are described in Supplementary Methods. For in vitro BrdU incorporation, cells labelled with 10 μM BrdU for 24 h were analysed using an APC BrdU Flow Kit (BD Biosciences). In vivo BrdU incorporation was performed as described (Kamata et al., 2010). For intracellular SPC staining, primary lung cells were fixed/permeabilised using a BD Cytofix/Cytoperm kit (BD Biosciences), and stained for SPC with bNPC2 (50 μg/ml) for 30 min were chased in serum-free DMEM for 3 h and then incubated with 200 nM Baf-A1 for 24 h.

**Immunofluorescence and filipin staining**

Cells cultured on coverslips were fixed in 4% (w/v) paraformaldehyde/PBS for 10 min, permeabilised in 0.4% (v/v) Triton-X/PBS for 10 min and incubated in blocking buffer (PBS containing 5% (w/v) bovine serum albumin) for 30 min. Samples for biotinylated primary antibody staining were further blocked for endogenous biotin using streptavidin solution (Vector Laboratories) for 15 min followed by incubation with 0.1% (w/v) biotin (Sigma)/PBS. Lung tissues were processed as described (Mercer et al., 2005). Primary antibody staining was performed in blocking buffer for 30 min at room temperature or for 16 h at 4°C, followed by secondary staining in blocking buffer containing AlexaFluor® 488-conjugated anti-rabbit IgG Fab (Invitrogen, 1:2,000) for 20 min at room temperature.

For intracellular un-esterified cholesterol vesicles. Aqueous solutions were deconvoluted using Huygens Essential software (Scientific Volume Imaging).

**Protein analysis**

Protein lysates were prepared as previously described (Kamata et al., 2010). For quantitative comparison of secreted proteins in CM, 2 × 10⁵ cells were cultured in a 6-cm dish in 2 ml DMEM for 72 h. CM was mixed with 4× SDS sample buffer (250 mM Tris–HCl pH 6.8, 8% (w/v) SDS, 40% (v/v) glycerol, 20% (v/v) β-mercaptoethanol) and boiled for 5 min. Western blots were performed by loading 20–40 μg cellular lysate or 18–25 μl CM sample per lane, as described (Kamata et al., 2010). Equal loading/transfer of CM samples was confirmed by Amido black staining of the membranes showing proteins around 70 kDa (containing serum albumin) for serum-containing samples, or around 45 kDa and 12 kDa (containing M2-marker YM1 and macrophage-lineage marker lysozyme C-2, respectively) for serum-free IMC-CM. Primary antibodies used for immunoblotting are described in Supplementary Methods. CM diluted at 1:100 was also subjected to CCL6 quantitation using a RayBio® Mouse CCL6 ELISA kit (RayBiotech) according to the manufacturer’s instructions.

**RT–PCR**

RNA was prepared as described (Noble et al., 2008). 0.5 μg RNA was reverse transcribed using Superscript III (Invitrogen) according to the manufacturer’s instructions, and 1 μl of the product was subjected to PCR using ReddyMix™ (Thermo Scientific). Quantitative RT–PCR was performed as described (Noble et al., 2008). Primers used are described in Supplementary Methods.

**Statistics**

Comparison between any two groups was performed by unpaired Welch’s t-test with assuming normal distribution of biological data. Bonferroni correction was applied for data analysis that needed multiple comparisons. Log-rank tests were used to evaluate differences in survival between two groups. Chi-square tests were used to evaluate differences in the frequency of the cells accumulated with un-esterified cholesterol vesicles.

**Supplementary information** for this article is available online: http://embomolmed.embopress.org

**Acknowledgements**

This work was funded by Cancer Research UK Programme grants (Ref C1362/A6969 and C1362/A13083). C.P. was also funded by a Royal Society-Wolfson Research Merit Award. We are indebted to the Department of Biomedical Services and the Advanced Imaging Facilities and Protein Nucleic Acid Chemistry Laboratory within Core Biotechnology Services at Leicester. We are also extremely grateful to Peter Lobel for providing the Npc2-mutant mice and NPC2-Alexa488.

**Author contributions**

TK and CP conceived and designed the entire study. TK, HJ, SG, BP, FP and CF performed experiments. TK analysed data and prepared figures. TK and CP wrote the manuscript.

© 2015 The Authors
The paper explained

Problem
Lung cancer is a major global health problem, accounting for 1.5 million deaths annually. Although numerous novel agents for the treatment of this disease have been developed in recent years, these are known to extend the survival of patients by only a few months. There is therefore an urgent need for the development of better preventative and treatment approaches. The most common form of lung cancer is the adenocarcinoma sub-type, and this disease arises from the accumulation of genetic damage within epithelial cells of the alveoli. Damage to KRAS or BRAF genes is known to be associated with lung adenocarcinoma development, and there has been considerable interest in understanding how this damage initiates and subsequently drives the disease. For this purpose, mouse models expressing mutated genes specifically in the lung have been implemented. Although the general intent of any anticancer strategy is to prevent the growth and dissemination of tumour cells, there is strong evidence that stromal cells also play a significant role and themselves represent important targets for interventional approaches. Here, we have used a mouse model expressing a mutated form of BRAF, known as \textit{v600e}BRAF, to characterise cells within the stroma and to investigate novel mechanisms involved in the recruitment of these cells to the tumour microenvironment.

Results
We show for the first time that cells within the microenvironment of \textit{v600e}BRAF lung adenomas are M2-polarised immature macrophages (termed IMCs) that are recruited to the tumour stroma by signalling through the chemokine receptor CCR1. These cells are important for tumour maintenance since treatment of mice with a CCR1 inhibitor significantly abrogates tumour burden. Furthermore, the level of recruitment of IMCs to the stroma is unusually regulated by the cholesterol-binding protein Niemann-Pick type C2 (NPC2). This protein is secreted by tumour cells and acts in a paracrine manner to suppress the secretion of CCR1 chemokines by IMCs.

Impact
These results reveal a previously unrecognised role for CCR1 signalling and NPC2 in modelling the microenvironment of early-stage lung cancer. Therefore, this evidence of a critical role of CCR1-driven IMC recruitment and NPC2 paracrine effects in lung cancer pathogenesis indicates that CCR1 blocking agents or agents that modulate NPC2 expression may be able to serve as new preventative tools in the management of lung cancer.

Conflict of interest
The authors declare that they have no conflict of interest.

References

NPC2 restrains macrophage recruitment

Tamiho Kamata et al


Subramanian K, Balch WE (2008) NPC1/NPC2 function as a tag team duo to mobilize cholesterol. Proc Natl Acad Sci USA 105: 15223 – 15224


Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5: 1 – 18


License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.